• العربية
  • فارسی
Brand
  • Iran Insight
  • Politics
  • Economy
  • Analysis
  • Special Report
  • Opinion
  • Podcast
  • Live TV
  • Iran Insight
  • Politics
  • Economy
  • Analysis
  • Special Report
  • Opinion
  • Podcast
  • Live TV
  • Theme
  • Language
    • العربية
    • فارسی
  • Iran Insight
  • Politics
  • Economy
  • Analysis
  • Special Report
  • Opinion
  • Podcast
  • Live TV
All rights reserved for Volant Media UK Limited
volant media logo

Iran drug stocks under two months, 800 medicines at risk as FX delays bite

Dec 14, 2025, 08:35 GMT+0Updated: 22:46 GMT+0

Iran’s medicine and infant-formula stocks average less than two months, with as many as 800 drug lines at risk of shortage within three months, industry representatives said, citing four-to-five-month delays in foreign-exchange allocation.

Babak Mesbahi, a presidium member of the Iranian Pharmacists Association, said sanctions are indirectly choking payment channels and logistics.

“Based on recent officials’ statements, the country’s medicine reserves on average are less than two months,” he said. “Infant formula faces a similar situation, and about 800 items will face shortages over the next three months.”

Mesbahi told Didban Iran that “Sanctions do not directly target medicine and infant formula, but their side effects are entirely palpable. Currency transfers have become difficult and allocation faces problems, and these issues are directly caused by sanctions.”

Asked whether the government has eased FX transfers, Mesbahi said: “As far as I know, nothing specific has been done. Right now there are pro forma invoices that have remained four to five months in the allocation and transfer queue,” he added.

The end of preferential exchange rates on many imported inputs has accelerated price rises for finished medicines and raw materials, according to pharmacists’ associations.

Hadi Ahmadi, a board member of the Iranian Pharmacists Association, said daily currency volatility and rising input costs are pushing up prices, even for common medicines.

“About 70% of production costs – packaging, auxiliaries and other inputs – follow the free-market exchange rate, and only roughly 30% relates to active ingredients, so price increases are unavoidable,” Ahmadi told ILNA.

“When prices rise and insurance does not keep pace, patients either take incomplete regimens or walk away, and the treatment path is disrupted.”

He added that only two to three million doses of influenza vaccine were imported versus a need of six to seven million for a population near 90 million, and distribution was late, which contributed to wider spread of flu.

Most Viewed

US pilot rescue inside Iran draws mockery of Guards
1

US pilot rescue inside Iran draws mockery of Guards

2

US, Iran hint at talks even as sanctions tighten and Hormuz tensions stay high

3
ANALYSIS

Iran's Saudi leverage could become its liability

4

IAEA raises alarm over Iran access amid mounting Hormuz tensions

5

Islamic Republic asks public to identify opponents abroad

Banner
Banner
Banner

Spotlight

  • ‘This is the cost you must pay’: Iran accused of denying food to death-row twin

    ‘This is the cost you must pay’: Iran accused of denying food to death-row twin

  • January's unfinished love stories: Lives severed by Iran protest killings

    January's unfinished love stories: Lives severed by Iran protest killings

  • After Muscat collapse, Tehran argues over what comes next
    ANALYSIS

    After Muscat collapse, Tehran argues over what comes next

  • Xi’s BRICS peace call sparks debate in Iran over China’s role in war

    Xi’s BRICS peace call sparks debate in Iran over China’s role in war

  • Iran's Saudi leverage could become its liability
    ANALYSIS

    Iran's Saudi leverage could become its liability

  • US pilot rescue inside Iran draws mockery of Guards

    US pilot rescue inside Iran draws mockery of Guards

  • Iran medical suppliers warn of worsening drug shortages

    Iran medical suppliers warn of worsening drug shortages